

BÖLÜM 23

Kanser Hastalarında Hepatit B Tedavisi

Ayşe NURANSOY CENGİZ¹

GİRİŞ

Amerikan Kanser Topluluğu (ACS)'nin 2021 raporuna göre, 2021'de yaklaşık 1,9 milyon yeni kanser vakasının teşhis edileceği öngörülmektedir. Yine, 600.000'den fazla kişinin kanserden öleceği tahmin edilmektedir (1). 1991 ila 2018 yılları arasında, kanserden ölüm oranı, 2017'den 2018'e %2,4'lük düşüş de dahil olmak üzere %31 düştüğü ortaya konmuştur (1). Bu 1 yıllık en büyük düşüş için yeni bir rekor olarak kabul edilmektedir. Ölümlerdeki düşüş, daha az insanın sigara içmesine, birçok kanser türünün daha erken teşhis edilmesine ve 1991'den 2018'e kadar 3,2 milyon daha az kanser ölümüne yol açan iyileştirilmiş tedavilere bağlanmaktadır (1). Kanserden ölüm oranları azalması immunsupresif hastaların artması sonucunu ortaya çıkarmaktadır. Bu durum, immunsupresif hastalarda görülen enfeksiyonların yaygınlığını artırmaktadır. Diğer yandan, enfeksiyonlar kanser hastalarında, altta yatan maligniteye ve çeşitli tedavi modalitelerine bağlı en sık görülen komplikasyonlar arasındadır (2).

Diğer yandan, Hepatit B virusu (HBV) tüm dünyada yaygın olarak görülmektedir. Yakın zamanda yapılan çalışmalara göre dünya çapında 248 milyon insanın HBV ile enfekte olduğu tahmin edilmektedir (3). Onkolojik hastalarda HBV reaktivasyonuna (HBVr) bakıldığında, HBV'nin serolojik durumuna ve spesifik kemoterapi rejimine bağlı olarak %30 ila %80 arasında değişmektedir (4). HBVr'u asemptomatik olabileceği gibi ciddi hepatite, karaciğer yetmezliğine ve ölüme yol açabilmektedir. Genellikle antineoplastik kemoterapide gecikmelere yol açarak tümörle ilişkili mortalitede artışa neden olabilmektedir (5).

¹ Uzm. Dr., Elbistan Devlet Hastanesi, İç Hastalıkları Kliniği, aysenuransoy@hotmail.com, OECD iD: 0000-0001-9133-8602

KAYNAKLAR

1. American Cancer Society Cancer Statistics 2021 Report. *J Nucl Med.* 2021;62:2021.
2. Chizuka A, Suda M, Shibata T, Kusumi E, Hori A, Hamaki T, Kodama Y, Horigome K, Kishi Y, Kobayashi K, Matsumura T, Yuji K, Tanaka Y, Kami M. Difference between hematological malignancy and Solid tumor research articles published in four major medical journals. *Leukemia.* 2006;20:1655–7.
3. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: A systematic review of data published between 1965 and 2013. *Lancet.* 2015;386:1546–55.
4. Hwang JP, Somerfield MR, Alston-Johnson DE, Cryer DR, Feld JJ, Kramer BS, Sabichi AL, Wong SL, Artz AS. Hepatitis B virus screening for patients with cancer before therapy: American Society of Clinical Oncology provisional clinical opinion update. *J Clin Oncol.* 2015;33:2212–20.
5. Loomba R, Liang TJ, Branch D, Diseases K. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies and future directions. *Gastroenterology.* 2018;152:1297–309.
6. Sasadeusz J, Grigg A, Hughes PD, Lee Lim S, Lucas M, McColl G, McLachlan SA, Peters MG, Shackel N, Slavin M, Sundararajan V, Thompson A, Doyle J, Rickard J, De Cruz P, Gish RG, Visvanathan K. Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Introduction and Immunology. *Clin Liver Dis.* 2019;23:487–92.
7. Cengiz M, Seckin Y, Cagin Y, Cengiz A. Investigation of hepatitis B virus prevalence and reactivation frequency in malignancy patients administering chemotherapy. *Ann Med Res.* 2021;28:2059.
8. Laiwathanapaisan R, Sripongpun P, Chamroonkul N, Dechaphunkul A, Sathitruangsak C, Sakdejayont S, Kongkamol C, Piratvisuth T. Hepatitis B screening rates and reactivation in solid organ malignancy patients undergoing chemotherapy in Southern Thailand. *Clin Mol Hepatol.* 2019;25:366–73.
9. Crosby J, Smith F, Ganti SS, Moka N, Bailey S. Hepatitis B Virus Reactivation Following Treatment of HNSCC With Cisplatin. *J Investig Med High Impact Case Reports.* 2022;10.
10. Zhu M, Wang H, Lou T, Xiong P, Zhang J, Li L, Sun Y, Wu Y. Current treatment of chronic hepatitis B: Clinical aspects and future directions. *Front Microbiol.* 2022;13:1–10.
11. Hwang, Jessica P. AS-FL. Management of patients with hepatitis B who require immunosuppressive therapy. *Nat Rev Gastroenterol Hepatol* [Internet]. 2014;11:209–19. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3624763/pdf/nihms412728.pdf>
12. Chang Y, Jeong SW, Jang JY. Hepatitis B Virus Reactivation Associated With Therapeutic Interventions. *Front Med.* 2022;8:1–9.
13. Hwang JP, Fisch MJ, Lok ASF, Zhang H, Vierling JM, Suarez-Almazor ME. Trends in hepatitis B virus screening at the onset of chemotherapy in a large US cancer center. *BMC Cancer* [Internet]. 2013;13:1. Available from: BMC Cancer
14. Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, Csako G. Systematic review: The effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. *Ann Intern Med.* 2008;148:519–28.
15. Tavakolpour S, Alavian SM, Sali S. Hepatitis B reactivation during immunosuppressive therapy or cancer chemotherapy, management, and prevention: A comprehensive review-screened. *Hepat Mon.* 2016;16.
16. Keam B, Lee JH, Im SA, Yoon JH. Why, when, and how to prevent hepatitis B virus reactivation in cancer patients undergoing chemotherapy. *JNCCN J Natl Compr Cancer Netw.* 2011;9:465–77.

17. Lubel JS, Angus PW. Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: Diagnosis and management. *J Gastroenterol Hepatol.* 2010;25:864–71.
18. Reddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter YT. American Gastroenterological Association Institute Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy. *Gastroenterology* [Internet]. 2015;148:215–9. Available from: <http://dx.doi.org/10.1053/j.gastro.2014.10.039>
19. Yeo W, Zee B, Zhong S, Chan PKS, Wong WL, Ho WM, Lam KC, Johnson PJ. Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. *Br J Cancer.* 2004;90:1306–11.
20. Long M, Jia W, Li S, Jin L, Wu J, Rao N, Feng H, Chen K, Deng H, Liu F, Su F, Song E. A single-center, prospective and randomized controlled study: Can the prophylactic use of lamivudine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy? *Breast Cancer Res Treat.* 2011;127:705–12.
21. Yu MW, Yeh SH, Chen PJ, Liaw YF, Lin CL, Liu CJ, Shih WL, Kao JH, Chen DS, Chen CJ. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: A prospective study in men. *J Natl Cancer Inst.* 2005;97:265–72.
22. Lau GKK, Leung YH, Fong DYT, Au WY, Kwong YL, Lie A, Hou JL, Wen YM, Nanj A, Liang R. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. *Blood* [Internet]. 2002;99:2324–30. Available from: <http://dx.doi.org/10.1182/blood.V99.7.2324>
23. Adrian M, Di Bisceglie, Anna S, Lok, Paul Martin, Norah Terrault, Robert P. Perrillo JHH. Recent US Food and Drug Administration Warnings on Hepatitis B Reactivation With Immune-Suppressing and Anticancer Drugs: Just the Tip of the Iceberg? *Hepatology.* 2015;61:703–11.
24. Lampertico P, Agarwal K, Berg T, Buti M, Janssen HLA, Papatheodoridis G, Zoulim F, Tacke F. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. *J Hepatol.* 2017;67:370–98.
25. Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. *Br J Haematol.* 2007;136:699–712.
26. Yu AS, Cheung RC, Keeffe EB. Hepatitis B vaccines. *Infect Dis Clin North Am.* 2006;20:27–45.
27. Wilson JN, Nokes DJ, Medley GF, Shouval D, Ilan Y. Immunization against hepatitis B through adoptive transfer of immunity. *Vaccine.* 1995;25:3705–12.
28. Shouval D, Ilan Y. Immunization against hepatitis B through adoptive transfer of immunity. *Intervirology.* 1995;38:41–6.
29. Shouval D, Shibolet O. Immunosuppression and HBV reactivation. *Semin Liver Dis.* 2013;33:167–77.
30. Lok ASF, McMahon BJ. Chronic hepatitis B: Update 2009. *Hepatology.* 2009;50:661–2.
31. Tong WD, Liu BH, Zhang LY, Zhang SB. Analysis of the c-kit gene in patients with slow transit constipation [2]. *Gut.* 2006;55:1207–8.